From target selection to the minimum acceptable biological effect level for human study: use of mechanism-based PK/PD modeling to design safe and efficacious biologics.

From target selection to the minimum acceptable biological effect level for human study: use of mechanism-based PK/PD modeling to design safe and efficacious biologics.

Item
http://www.wikidata.org/entity/Q34901024
Agonistic TAM-163 antibody targeting tyrosine kinase receptor-B: applying mechanistic modeling to enable preclinical to clinical translation and guide clinical trial designPrediction of clinical pharmacokinetics of AMG 181, a human anti-α 4 β 7 monoclonal antibody for treating inflammatory bowel diseasesA First-in-Human Study To Assess the Safety and Pharmacokinetics of Monoclonal Antibodies against Human Cytomegalovirus in Healthy VolunteersFactors influencing magnitude and duration of target inhibition following antibody therapy: implications in drug discovery and development.Clinical pharmacology considerations in biologics development.AFIR: A Dimensionless Potency Metric for Characterizing the Activity of Monoclonal Antibodies.Qualification of a free ligand assay in the presence of anti-ligand antibody Fab fragments.A Tutorial on Target-Mediated Drug Disposition (TMDD) Models.
P2860

From target selection to the minimum acceptable biological effect level for human study: use of mechanism-based PK/PD modeling to design safe and efficacious biologics.

Item
http://www.wikidata.org/entity/Q34901024
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
From target selection to the m ...... afe and efficacious biologics.
@ast
From target selection to the m ...... afe and efficacious biologics.
@en
From target selection to the m ...... afe and efficacious biologics.
@nl
type
label
From target selection to the m ...... afe and efficacious biologics.
@ast
From target selection to the m ...... afe and efficacious biologics.
@en
From target selection to the m ...... afe and efficacious biologics.
@nl
prefLabel
From target selection to the m ...... afe and efficacious biologics.
@ast
From target selection to the m ...... afe and efficacious biologics.
@en
From target selection to the m ...... afe and efficacious biologics.
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P407
P433
P478
P577
P5875
P6179
P698
P932
P356
P1433
P1476
From target selection to the m ...... afe and efficacious biologics.
@en
P2093
P2860
P2888
P304
P31
P356
P407
P433
P478
P577
P5875
P6179
P698
P932